Pfizer and AbbVie held onto their number one and two rankings on the Scrip 100 in Outlook 2025 even as both companies faced steep declines in 2023 pharmaceutical revenues. But some drug manufacturers in the top 20 rankings moved either up or down on the leaderboard, which can be seen at the bottom of this article.
The Scrip 100: Changes At The Top Of The Leaderboard
Pfizer continued its reign as the Scrip 100 leader for a third year, while Lilly and Novo climbed higher.
More from Outlook
• By
The financial macroenvironment may be looking more favorable for 2025 but will pharma growth be muted by elements beyond its control? In Vivo discusses the headwinds and drivers for pharma in the coming 12 months.
• By
Despite the stellar success of the class so far, biotech is now looking past GLP-1s to more tolerable, sustainable approaches to obesity.
• By
Former Roche CEO Bill Burns reflects on transforming Roche into a global leader in specialty care and oncology. Now, as he spearheads efforts to combat antibiotic resistance, Burns shares insights on industry evolution, the power of cultural change, and the urgent need for a new business model in antibiotics development.
• By
The Top 100 ranking of global medtechs by revenues for 2023 illustrated how the leaders continue to tailor innovation to users and patients according to market trends while driving portfolio management for growth.